GOLDMAN; Samuel

Patent Applications and Registrations

Patent applications and USPTO patent grants for GOLDMAN; Samuel.The latest application filed is for "techniques for live-writing and editing closed captions".

Company Profile

0.15.12

GOLDMAN; Samuel - Brooklyn NY
Goldman; Samuel - Acton MA

*profile and listings may contain filings by different individuals or companies with the same name. Review application materials to confirm ownership/assignment.

Patent Activity

Patent	Date
Techniques For Live-writing And Editing Closed Captions App 20150098018 - STARLING; Michael Irving ; et al.	2015-04-09
Use of IL-12 and IL-12 Antagonists in the Treatment of Autoimmune Diseases App 20130089515 - Leonard; John ; et al.	2013-04-11
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Grant 8,231,874 - Leonard , et al. July 31, 2	2012-07-31
Use Of Il-12 And Il-12 Antagonists In The Treatment Of Autoimmune Diseases App 20120020916 - Leonard; John ; et al.	2012-01-26
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Grant 8,012,475 - Leonard , et al. September 6, 2	2011-09-06
Methods of treatment of autoimmune diseases using humanized immunoglobulin reactive with B7-2 Grant 7,666,421 - Co , et al. February 23, 2	2010-02-23
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases App 20090263351 - Leonard; John ; et al.	2009-10-22
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Grant 7,534,430 - Leonard , et al. May 19, 2	2009-05-19
Methods for modulation of immune responses using humanized immunoglobulins reactive with B7-1 molecules Grant 7,531,175 - Co , et al. May 12, 2	2009-05-12
Human Il-17f And Other Il-17f-related Proteins And Methods Related Thereto App 20090075884 - Jacobs; Kenneth ; et al.	2009-03-19
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases App 20070020233 - Leonard; John ; et al.	2007-01-25
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases Grant 7,138,115 - Leonard , et al. November 21, 2	2006-11-21
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith App 20060251645 - Co; Man Sung ; et al.	2006-11-09
Method of transplanting cells by contacting donor cells with B7-1-and B7-2-specific immunoglobulins Grant 6,984,383 - Co , et al. January 10, 2	2006-01-10
Humanized immunoglobulin reactive with B7-2 and methods of treatment therewith Grant 6,972,125 - Co , et al. December 6, 2	2005-12-06
Antibodies to human IL-17F and other CTLA-8-related proteins and methods related thereto App 20050214315 - Jacobs, Kenneth ; et al.	2005-09-29
Humanized immunoglobulin reactive with B7 molecules and methods of treatment therewith App 20050208042 - Co, Man Sung ; et al.	2005-09-22
Humanized immunoglobulin reactive with B7 therewith Grant 6,913,747 - Co , et al. July 5, 2	2005-07-05
Antibodies to human IL-17F and other CTLA-8-related proteins Grant 6,902,735 - Jacobs , et al. June 7, 2	2005-06-07
Use of IL-12 and IL-12 antagonists in the treatment of autoimmune diseases App 20050079177 - Leonard, John P. ; et al.	2005-04-14
Use of IL-12 antagonists in the treatment of rheumatoid arthritis Grant 6,830,751 - Leonard , et al. December 14, 2	2004-12-14
Humanized immunoglobulin reactive with b7-2 and methods of treatment therewith Grant 6,827,934 - Co , et al. December 7, 2	2004-12-07
Use of IL-12 antagonists in the treatment of conditions promoted by an increase in levels of IFN-y Grant 6,706,264 - Leonard , et al. March 16, 2	2004-03-16
Humanized Immunoglobulin Reactive With B7-2 And Methods Of Treatment Therewith App 20020176855 - CO, MAN SUNG ; et al.	2002-11-28
Polynucleotides encoding human CTLA-8 related proteins Grant 6,074,849 - Jacobs , et al. June 13, 2	2000-06-13
Human CTLA-8 and uses of CTLA-8-related proteins Grant 6,043,344 - Jacobs , et al. March 28, 2	2000-03-28

uspto.report is an independent third-party trademark research tool that is not affiliated, endorsed, or sponsored by the United States Patent and Trademark Office (USPTO) or any other governmental organization. The information provided by uspto.report is based on publicly available data at the time of writing and is intended for informational purposes only.

While we strive to provide accurate and up-to-date information, we do not guarantee the accuracy, completeness, reliability, or suitability of the information displayed on this site. The use of this site is at your own risk. Any reliance you place on such information is therefore strictly at your own risk.

All official trademark data, including owner information, should be verified by visiting the official USPTO website at www.uspto.gov. This site is not intended to replace professional legal advice and should not be used as a substitute for consulting with a legal professional who is knowledgeable about trademark law.